Treatment D), prior to the MMTT on Day 3 provided greater postprandial PG reduction versus
placebo (difference in incremental glucose AUC0–2h, −7.5% for B vs A; −18.5% for C vs A;
−12.0% [P = 0.012] for C vs B), leading to modestly greater reductions in total glucose AUC0–2h
with Treatment C versus Treatment B or D. Canagliflozin was generally well tolerated.
Conclusions. These findings suggest that a non-renal mechanism (ie, beyond UGE)
contributes to glucose lowering for canagliflozin 300 mg, but not 150 mg.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY